NEW YORK & GENEVA--(BUSINESS WIRE)--Neurosterix, a biopharmaceutical company dedicated to the development of allosteric modulator therapeutics for underserved neurological disorders, launched today ...
Recent research published in Communications Biology marks an advance in structural biology by enhancing understanding of ...
About GT-02287 Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, ...
Researchers at the Centre for Genomic Regulation have developed a new technique for identifying allosteric sites in proteins (Nature 2022, DOI: 10.1038/s41586-022-04586-4). While many drugs target the ...
Researchers at the University of Melbourne have identified a hidden allosteric mechanism that activates ICL2, a key enzyme in ...
Researchers have identified a hidden allosteric 'on switch' in the ICL2 enzyme of Mycobacterium tuberculosis, offering a new pathway to target drug-resistant strains. Using advanced imaging at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results